Literature DB >> 10797230

The TIPP opioid peptide family: development of delta antagonists, delta agonists, and mixed mu agonist/delta antagonists.

P W Schiller1, G Weltrowska, I Berezowska, T M Nguyen, B C Wilkes, C Lemieux, N N Chung.   

Abstract

The discovery of the prototype delta opioid antagonists TIPP (H-Tyr-Tic-Phe-Phe-OH) and TIP (H-Tyr-Tic-Phe-OH) in 1992 was followed by extensive structure-activity relationship studies, leading to the development of analogues that are of interest as pharmacological tools or as potential therapeutic agents. Stable TIPP-derived delta opioid antagonists with subnanomolar delta receptor binding affinity and extraordinary delta receptor selectivity include TIPP[Psi] (H-Tyr-TicPsi[CH(2)NH]Phe-Phe-OH] and TICP[Psi] (H-Tyr-TicPsi[CH(2)NH]Cha-Phe-OH); Cha: cyclohexylalanine), which are widely used in opioid research. Theoretical conformational analyses in conjunction with the pharmacological characterization of conformationally constrained TIPP analogues led to a definitive model of the receptor-bound conformation of H-Tyr-Tic-(Phe-Phe)-OH-related delta opioid antagonists, which is characterized by all-trans peptide bonds. Further structure-activity studies revealed that the delta antagonist vs delta agonist behavior of TIP(P)-derived compounds depended on very subtle structural differences in diverse locations of the molecule and suggested a delta receptor model involving a number of different inactive receptor conformations. A further outcome of these studies was the identification of a new class of potent and very selective dipeptide delta agonists of the general formula H-Tyr-Tic-NH-X (X = arylalkyl), which are of interest for drug development because of their low molecular weight and lipophilic character. Most interestingly, TIPP analogues containing a C-terminal carboxamide group displayed a mixed mu agonist/delta antagonist profile, and thus were expected to be analgesics with a low propensity to produce tolerance and physical dependence. This turned out to be the case with the TIPP-derived mu agonist/delta antagonist DIPP-NH(2)[Psi] (H-Dmt-TicPsi[CH(2)NH]Phe-Phe-NH(2)); Dmt: 2',6'- dimethyltyrosine). Copyright 2000 John Wiley & Sons, Inc.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10797230     DOI: 10.1002/(SICI)1097-0282(1999)51:6<411::AID-BIP4>3.0.CO;2-Z

Source DB:  PubMed          Journal:  Biopolymers        ISSN: 0006-3525            Impact factor:   2.505


  24 in total

1.  Bifunctional μ/δ opioid peptides: variation of the type and length of the linker connecting the two components.

Authors:  Jinguo Ding; Carole Lemieux; Nga N Chung; Peter W Schiller
Journal:  Chem Biol Drug Des       Date:  2012-01-04       Impact factor: 2.817

Review 2.  Targeting opioid receptor heterodimers: strategies for screening and drug development.

Authors:  Achla Gupta; Fabien M Décaillot; Lakshmi A Devi
Journal:  AAPS J       Date:  2006-03-10       Impact factor: 4.009

3.  Quantitative conformationally sampled pharmacophore for delta opioid ligands: reevaluation of hydrophobic moieties essential for biological activity.

Authors:  Denzil Bernard; Andrew Coop; Alexander D MacKerell
Journal:  J Med Chem       Date:  2007-03-17       Impact factor: 7.446

4.  Evolution of the Bifunctional Lead μ Agonist / δ Antagonist Containing the Dmt-Tic Opioid Pharmacophore.

Authors:  Gianfranco Balboni; Severo Salvadori; Claudio Trapella; Brian I Knapp; Jean M Bidlack; Lawrence H Lazarus; Xuemei Peng; John L Neumeyer
Journal:  ACS Chem Neurosci       Date:  2010-02-17       Impact factor: 4.418

5.  Bioluminescence resonance energy transfer assays reveal ligand-specific conformational changes within preformed signaling complexes containing delta-opioid receptors and heterotrimeric G proteins.

Authors:  Nicolas Audet; Céline Galés; Elodie Archer-Lahlou; Marc Vallières; Peter W Schiller; Michel Bouvier; Graciela Pineyro
Journal:  J Biol Chem       Date:  2008-04-01       Impact factor: 5.157

6.  Novel opioid peptide derived antagonists containing (2S)-2-methyl-3-(2,6-dimethyl-4-carbamoylphenyl)propanoic acid [(2S)-Mdcp].

Authors:  Animesh Ghosh; Jie Luo; Chen Liu; Grazyna Weltrowska; Carole Lemieux; Nga N Chung; Yixin Lu; Peter W Schiller
Journal:  J Med Chem       Date:  2008-09-25       Impact factor: 7.446

Review 7.  Opioid receptor trafficking and interaction in nociceptors.

Authors:  X Zhang; L Bao; S Li
Journal:  Br J Pharmacol       Date:  2014-07-01       Impact factor: 8.739

Review 8.  Identifying ligand-specific signalling within biased responses: focus on δ opioid receptor ligands.

Authors:  I Charfi; N Audet; H Bagheri Tudashki; G Pineyro
Journal:  Br J Pharmacol       Date:  2014-07-01       Impact factor: 8.739

Review 9.  Bi- or multifunctional opioid peptide drugs.

Authors:  Peter W Schiller
Journal:  Life Sci       Date:  2009-03-11       Impact factor: 5.037

10.  CNS delivery and pharmacokinetic evaluations of DALDA analgesic peptide analog administered in Nano-sized oil-in-water emulsion formulation.

Authors:  Lipa Shah; Florence Gattacceca; Mansoor M Amiji
Journal:  Pharm Res       Date:  2013-12-03       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.